Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy

Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, provides an overview if the Phase III clinical trial of ibrutinib vs chlorambucil in chronic lymphocytic leukemia (CLL) patients over the age of 65. Progression free survival (PFS) and overall survival (OS) were increased in the ibrutinib arm, demonstrating the superior efficacy of this drug over chlorambucil.